Disc Medicine Inc (IRON)
29.79
+0.79
(+2.72%)
USD |
NASDAQ |
May 03, 16:00
29.79
0.00 (0.00%)
After-Hours: 20:00
Disc Medicine Cash from Financing (TTM): 239.38M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 239.38M |
September 30, 2023 | 380.44M |
June 30, 2023 | 380.00M |
March 31, 2023 | 226.23M |
December 31, 2022 | 148.98M |
September 30, 2022 | -102.57M |
June 30, 2022 | -103.84M |
Date | Value |
---|---|
March 31, 2022 | -105.51M |
December 31, 2021 | 89.93M |
September 30, 2021 | 192.80M |
June 30, 2021 | 208.05M |
March 31, 2021 | 209.64M |
December 31, 2020 | 34.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-105.51M
Minimum
Mar 2022
380.44M
Maximum
Sep 2023
138.29M
Average
192.80M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Neogen Corp | 2.251M |
SIGA Technologies Inc | -43.42M |
AbbVie Inc | -211.00M |
Bristol-Myers Squibb Co | 8.278B |
Amylyx Pharmaceuticals Inc | 3.543M |